The Current Diagnostic Pathway is Inadequate
Every year, CT scans reveal a lung spot or mass in 15 million people worldwide. A CT scan cannot determine whether the mass is malignant (i.e., cancerous) or benign. Because there is not an immediate and non-invasive way to identify malignancy in the lungs, repeated CT scans are prescribed up to 6 times for up to 3½ years to detect growth in the mass, an indication of cancer. By the time this growth is detected, the cancer has often progressed to the point that treatment is ineffective. Thus, patients must undergo repeated exposure to radiation and prolonged waiting for a lung cancer diagnosis.
The Electro Pulmonary Nodule Scan
The EPN Scan uses an established bio-conductance technology – similar to an EEG or EKG, to risk stratify patients who are likely to have lung lesions suspicious for cancer. The patented computerized Scan can be used in conjunction with Low-Dose CT screening to evaluate masses identified by these scans for high or low risk of malignancy.
Enabling Early Detection of Lung Cancer
The EPN Scan is performed on patients who have a lesion or mass in their lungs that was identified by a CT scan as suspicious for lung cancer. The proprietary test uses an electrical current similar to an EKG to immediately identify a patient’s risk.
Electro Pulmonary Nodule Scan Report
The EPN Scan captures thousands of precise measurements and produces a risk stratification composite score that provides the physician, surgeon, and patient with additional information in determining the risk of a suspicious lung mass being malignant.